Want to see RVPH full AI Analyst Report?
RVPH Stock Chart & Stats
$0.50
$0.03(6.18%)
At close: 4:00 PM EDT
$0.50
$0.03(6.18%)
Day’s Range― - ―
52-Week Range$0.26 - $17.20
Previous CloseN/A
Volume68.37K
Average Volume (3M)36.82K
Market Cap
$6.95M
Enterprise Value-$11.44
Total Cash (Recent Filing)$19.89T
Total Debt (Recent Filing)$144.09B
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 16, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.96
Shares Outstanding13,110,377
10 Day Avg. Volume29,700
30 Day Avg. Volume36,820
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.82
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker Validation And Trial EnrichmentPublished vocal biomarker findings and identification of speech latency as a predictive biomarker increase trial visibility and enable selection of patients with more severe negative symptoms to strengthen the treatment signal versus placebo.
Clinical Efficacy And SafetyClinical trial results indicate brilaroxazine has a favorable safety profile and potential effectiveness in treating schizophrenia, supporting a meaningful commercial opportunity if efficacy is replicated.
Regulatory ClarityFDA recommendation for a second confirmatory Phase 3 study establishes a clear regulatory pathway toward a future drug application, reducing regulatory uncertainty for development planning.
Bears Say
Cash Runway And Financing NeedA recent capital infusion supports initiation of a second Phase 3 trial but does not eliminate the need for additional financing, with operating losses and limited cash resources constraining the company's runway.
Equity Dilution And Analyst DowngradeAnalyst's recommendation was downgraded to Hold following a reverse stock split and a significantly dilutive equity financing, reflecting downward pressure on the share price from dilution.
Listing And Delisting RiskShares trading below the NASDAQ minimum listing threshold increase the risk of delisting and create additional downside pressure on the stock.
Reviva Pharmaceuticals Holdings News
RVPH FAQ
What was Reviva Pharmaceuticals Holdings’s price range in the past 12 months?
Reviva Pharmaceuticals Holdings lowest stock price was $0.26 and its highest was $17.20 in the past 12 months.
What is Reviva Pharmaceuticals Holdings’s market cap?
Reviva Pharmaceuticals Holdings’s market cap is $6.95M.
When is Reviva Pharmaceuticals Holdings’s upcoming earnings report date?
Reviva Pharmaceuticals Holdings’s upcoming earnings report date is Nov 16, 2026 which is in 71 days.
How were Reviva Pharmaceuticals Holdings’s earnings last quarter?
Reviva Pharmaceuticals Holdings released its earnings results on Aug 12, 2026. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.385 by $0.195.
Is Reviva Pharmaceuticals Holdings overvalued?
According to Wall Street analysts Reviva Pharmaceuticals Holdings’s price is currently Overvalued.
Does Reviva Pharmaceuticals Holdings pay dividends?
Reviva Pharmaceuticals Holdings does not currently pay dividends.
What is Reviva Pharmaceuticals Holdings’s EPS estimate?
Reviva Pharmaceuticals Holdings’s EPS estimate is -0.29.
How many shares outstanding does Reviva Pharmaceuticals Holdings have?
Reviva Pharmaceuticals Holdings has 13,110,377 shares outstanding.
What happened to Reviva Pharmaceuticals Holdings’s price movement after its last earnings report?
Reviva Pharmaceuticals Holdings reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.385. Following the earnings report the stock price went up 9.565%.
Which hedge fund is a major shareholder of Reviva Pharmaceuticals Holdings?
Currently, no hedge funds are holding shares in RVPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Reviva Pharmaceuticals Holdings
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Technical Analysis
Ownership Overview
16.02%
Insiders
0.91% Mutual Funds
0.05% Other Institutional Investors
83.02% Public Companies and
Individual Investors